Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-02-28 00:00:00 ET · period of report 2023-02-24 · accession 0001209191-23-013695 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-02-28 | 2023-02-27 | VRTX | Ambrose Kristen | SVP, CAO | S - Sale | $287.55 | -1,207 | 7,528 | -14% | -$347.1K |
| 2023-02-28 | 2023-02-24 | VRTX | Ambrose Kristen | SVP, CAO | F - Tax | $289.12 | -502 | 8,510 | -6% | -$145.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-27 | S | D | 42 | $289.63 | 7,303 | D | — | — | |
| 2 | Common | Common Stock | 2023-02-27 | S | D | 183 | $288.68 | 7,345 | D | — | — | (F2) Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F4) Open market sales reported on this line occurred at a weighted average price of $288.68 (range $288.24 to $289.17). |
| 3 | Common | Common Stock | 2023-02-24 | F | D | 502 | $289.12 | 8,510 | D | — | — | |
| 4 | Common | Common Stock | 2023-02-27 | S | D | 982 | $287.25 | 7,528 | D | — | — | (F3) Open market sales reported on this line occurred at a weighted average price of $287.25 (range $286.79 to $287.71). (F2) Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |